TABLE 1.

Summary of patient characteristics and viral kinetic parameters

Cohort and patient no.	Age at entry	Prior therapy	Baseline % CD4	Baseline RNA (copies/ml)	δa	T1b (days)	R1c (%)	μd	T2e	R2f (%)
Cohort 1
1	15 days	ZDV, 2 wk	34	4.93	0.56	1.23	89.3	0.04	15.38	10.7
2	1.1 mo	ZDV, 4 wk	47	5.90	0.26	2.69	98.3	0.02	33.26	1.7
3	2.7 mo	ZDV, 10 wk	35	4.81	1.03	0.67	98.6	0.03	23.13	1.4
4	2.8 mo	ZDV, 6 wk	14	5.92	0.32	2.18	95.7	0.04	16.51	4.3
5	3.0 mo	None	24	6.82	0.59	1.17	98.2	0.04	17.17	1.8
Range (median)			14–47 (34)	4.93–6.82 (5.90)	0.26–1.03 (0.56)	0.67–2.69 (1.23)	89.3–98.6 (98.2)	0.02–0.04 (0.04)	15.38–33.26 (17.17)	1.8–10.7 (1.8)
Cohort 2
6	3.6 mo	None	45	6.38	1.04	0.66	99.8	0.06	11.48	0.2
7	4.0 mo	None	48	5.70	1.22	0.57	99.2	0.06	11.58	0.8
8	7.7 mo	None	41	6.47	1.20	0.58	99.5	0.06	11.27	0.5
9	10.4 mo	None	41	5.03	0.97	0.71	95.5	0.11	6.31	4.5
10	13.8 mo	None	14	6.29	1.14	0.61	99.3	0.06	12.26	0.7
11	19.2 mo	None	24	5.22	1.04	0.66	99.0	0.12	5.97	1.0
12	24.3 mo	None	38	4.70	2.02	0.34	99.6	0.15	4.68	0.4
Range (median)			14–48 (41)	4.70–6.47 (5.70)	0.97–2.02 (1.14)	0.34–0.71 (0.61)	95.5–99.8 (99.3)	0.06–0.15 (0.06)	4.68–12.26 (11.27)	0.2–4.5 (0.7)

^aδ = first-phase viral decay rate. Cohort 1 versus cohort 2, P = 0.0051 (Wilcoxon rank sum test). 

^bT₁ = first-phase viral half-life (days). 

^cR₁ = percentage of plasma virus cleared during first phase. 

^dμ = second-phase viral decay rate. Cohort 1 versus Cohort 2, P = 0.0025 (Wilcoxon rank sum test). 

^eT₂ = second-phase viral half-life (days). 

^fR₂ = percentage of plasma virus cleared during the second phase.